Aarti Pharmalabs opens new Tarapur block, adds 3600 TPA Xanthine capacity

Aarti Pharmalabs has inaugurated an additional manufacturing block at its Tarapur Unit 5 in Maharashtra, adding 3600 tonnes per annum of Xanthine derivatives capacity. Total capacity now stands at 9600 TPA, placing the company among the top three global Xanthine derivatives manufacturers. All required approvals have been secured, trial production has begun, and the facility will ramp up to optimum utilisation over the coming quarters. Chairman Rashesh Gogri called it a significant milestone that strengthens the company's ability to serve large customers.